204 related articles for article (PubMed ID: 20623262)
1. Recurrence after and complications associated with adjuvant treatments for sacral giant cell tumor.
Ruggieri P; Mavrogenis AF; Ussia G; Angelini A; Papagelopoulos PJ; Mercuri M
Clin Orthop Relat Res; 2010 Nov; 468(11):2954-61. PubMed ID: 20623262
[TBL] [Abstract][Full Text] [Related]
2. Surgical margins and local control in resection of sacral chordomas.
Ruggieri P; Angelini A; Ussia G; Montalti M; Mercuri M
Clin Orthop Relat Res; 2010 Nov; 468(11):2939-47. PubMed ID: 20635173
[TBL] [Abstract][Full Text] [Related]
3. Conservative surgery for giant cell tumors of the sacrum. The role of cryosurgery as a supplement to curettage and partial excision.
Marcove RC; Sheth DS; Brien EW; Huvos AG; Healey JH
Cancer; 1994 Aug; 74(4):1253-60. PubMed ID: 8055446
[TBL] [Abstract][Full Text] [Related]
4. Outcome of conservative surgery for giant cell tumor of the sacrum.
Guo W; Ji T; Tang X; Yang Y
Spine (Phila Pa 1976); 2009 May; 34(10):1025-31. PubMed ID: 19404178
[TBL] [Abstract][Full Text] [Related]
5. Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision.
van der Heijden L; van de Sande MA; van der Geest IC; Schreuder HW; van Royen BJ; Jutte PC; Bramer JA; Öner FC; van Noort-Suijdendorp AP; Kroon HM; Dijkstra PD
Eur Spine J; 2014 Sep; 23(9):1949-62. PubMed ID: 24614982
[TBL] [Abstract][Full Text] [Related]
6. Can Navigation-assisted Surgery Help Achieve Negative Margins in Resection of Pelvic and Sacral Tumors?
Abraham JA; Kenneally B; Amer K; Geller DS
Clin Orthop Relat Res; 2018 Mar; 476(3):499-508. PubMed ID: 29529631
[TBL] [Abstract][Full Text] [Related]
7. Analysis of risk factors for recurrence of giant cell tumor of the sacrum and mobile spine combined with preoperative embolization.
Ming Z; Kangwu C; Huilin Y; Genlin W; Jian L; Yiming J; Chunshen W; Chao C
Turk Neurosurg; 2013; 23(5):645-52. PubMed ID: 24101313
[TBL] [Abstract][Full Text] [Related]
8. What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma?
Ji T; Guo W; Yang R; Tang X; Wang Y; Huang L
Clin Orthop Relat Res; 2017 Mar; 475(3):620-630. PubMed ID: 26975382
[TBL] [Abstract][Full Text] [Related]
9. Decision making in primary sacral tumors.
Puri A; Agarwal MG; Shah M; Srinivas CH; Shukla PJ; Shrikhande SV; Jambhekar NA
Spine J; 2009 May; 9(5):396-403. PubMed ID: 19059810
[TBL] [Abstract][Full Text] [Related]
10. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy.
; Becker WT; Dohle J; Bernd L; Braun A; Cserhati M; Enderle A; Hovy L; Matejovsky Z; Szendroi M; Trieb K; Tunn PU
J Bone Joint Surg Am; 2008 May; 90(5):1060-7. PubMed ID: 18451399
[TBL] [Abstract][Full Text] [Related]
11. Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature.
Martin C; McCarthy EF
Iowa Orthop J; 2010; 30():69-75. PubMed ID: 21045974
[TBL] [Abstract][Full Text] [Related]
12. Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.
Agarwal MG; Gundavda MK; Gupta R; Reddy R
Clin Orthop Relat Res; 2018 Sep; 476(9):1773-1782. PubMed ID: 30794215
[TBL] [Abstract][Full Text] [Related]
13. Giant cell tumor with pathologic fracture: should we curette or resect?
van der Heijden L; Dijkstra PD; Campanacci DA; Gibbons CL; van de Sande MA
Clin Orthop Relat Res; 2013 Mar; 471(3):820-9. PubMed ID: 22926445
[TBL] [Abstract][Full Text] [Related]
14. Sacrectomy and adjuvant radiotherapy for the treatment of sacral chordomas: a single-center experience over 27 years.
Dhawale AA; Gjolaj JP; Holmes L; Sands LR; Temple HT; Eismont FJ
Spine (Phila Pa 1976); 2014 Mar; 39(5):E353-9. PubMed ID: 24365895
[TBL] [Abstract][Full Text] [Related]
15. Long-term administration of bisphosphonate to reduce local recurrence of sacral giant cell tumor after nerve-sparing surgery.
Xu W; Wang Y; Wang J; Yang X; Liu W; Zhou W; Liu T; Xiao J
J Neurosurg Spine; 2017 Jun; 26(6):716-721. PubMed ID: 28338455
[TBL] [Abstract][Full Text] [Related]
16. Supplemental Bone Grafting in Giant Cell Tumor of the Extremity Reduces Nononcologic Complications.
Benevenia J; Rivero SM; Moore J; Ippolito JA; Siegerman DA; Beebe KS; Patterson FR
Clin Orthop Relat Res; 2017 Mar; 475(3):776-783. PubMed ID: 26932739
[TBL] [Abstract][Full Text] [Related]
17. Soft tissue extension increases the risk of local recurrence after curettage with adjuvants for giant-cell tumor of the long bones.
van der Heijden L; van de Sande MA; Dijkstra PD
Acta Orthop; 2012 Aug; 83(4):401-5. PubMed ID: 22880716
[TBL] [Abstract][Full Text] [Related]
18. Surgery methods and soft tissue extension are the potential risk factors of local recurrence in giant cell tumor of bone.
Li D; Zhang J; Li Y; Xia J; Yang Y; Ren M; Liao Y; Yu S; Li X; Shen Y; Zhang Y; Yang Z
World J Surg Oncol; 2016 Apr; 14():114. PubMed ID: 27094617
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of Giant Cell Tumor of the Spine after Resection: A Report of 10 Cases.
Lin P; Lin N; Teng W; Wang SD; Pan WB; Huang X; Yan XB; Liu M; Li HY; Li BH; Sun LL; Wang Z; Zhou XZ; Ye ZM
Orthop Surg; 2018 May; 10(2):107-114. PubMed ID: 29878714
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for the local recurrence of giant cell tumours of the sacrum treated with nerve-sparing surgery.
Zhao Y; Tang X; Yan T; Ji T; Yang R; Guo W
Bone Joint J; 2020 Oct; 102-B(10):1392-1398. PubMed ID: 32993346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
